AlzeCure Pharma AB (OSTO:ALZCUR) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AlzeCure Pharma AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AlzeCure Pharma AB's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

AlzeCure Pharma AB's long-term debt to total assets ratio stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).

AlzeCure Pharma AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for AlzeCure Pharma AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB LT-Debt-to-Total-Asset Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

AlzeCure Pharma AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

AlzeCure Pharma AB LT-Debt-to-Total-Asset Calculation

AlzeCure Pharma AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	32.001
	=

AlzeCure Pharma AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	0	/	47.257
	=

AlzeCure Pharma AB (OSTO:ALZCUR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AlzeCure Pharma AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (OSTO:ALZCUR) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AC6:Germany

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines